United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.68, $1.13 better than the analyst estimate of $2.55. Revenue for the quarter came in at $404.9 million versus the consensus estimate of $388.29 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.